Navigation Links
Cornerstone Therapeutics to Host First Quarter 2009 Conference Call
Date:4/27/2009

CARY, N.C., April 27 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (NasdaqCM: CRTX), a specialty pharmaceutical company focused on developing and commercializing prescription medications for respiratory disorders, today announced that it will host a conference call at 8:30 AM ET on Thursday, May 7, 2009, to discuss its financial results for the quarter ended March 31, 2009. Management will also provide an update on the Company's strategy, operations and product development pipeline. Cornerstone intends to issue its financial results press release before the market opens on May 7th.

To participate in the live conference call, please dial 866-783-2137 (U.S. callers) or 857-350-1596 (international), and provide passcode 84050385. A live webcast of the call will also be available through the Investor Relations section of the Company's Web site. Please allow extra time prior to the webcast to register, download and install any necessary audio software.

The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days, beginning at 11:30 AM ET on May 7th at 888-286-8010 (U.S. callers) or 617-801-6888 (international), and provide passcode 21539068.

About Cornerstone Therapeutics

Cornerstone Therapeutics (NasdaqCM: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing prescription products for the respiratory market. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. The Company also has a late-stage clinical pipeline with six regulatory approval submissions targeted within the next three years. The Company's commercial strategy is to grow market share for its currently marketed products using its sales and marketing capabilities, acquire non-promoted or underperforming branded pharmaceutical products and implement life cycle management techniques to maximize the value of its currently marketed products, newly acquired products and product candidates that are in development.

Safe Harbor Statement

Statements in this press release regarding the progress and timing of our product development programs and related trials; our future opportunities; our strategy, future operations, financial position, future revenues and projected costs; our management's prospects, plans and objectives; and any other statements about management's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Any statements that are not statements of historical fact (including, without limitation, statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "plans," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements.

There are a number of important factors that could cause our actual results or events to differ materially from those indicated by such forward-looking statements, including risks relating to our ability to develop and maintain the necessary sales, marketing, supply chain, distribution and manufacturing capabilities to commercialize our products, including difficulties relating to the manufacturing of ZYFLO CR(R) tablets; the possibility that the Food and Drug Administration (the FDA) will take enforcement action against us or one or more of our marketed drugs which do not have FDA-approved marketing applications; patient, physician and third-party payor acceptance of our products as safe and effective therapeutic products; our heavy dependence on the commercial success of a small number of currently marketed products; our ability to maintain regulatory approvals to market and sell our products that do have FDA-approved marketing applications; our ability to enter into additional strategic licensing, collaboration or co-promotion transactions on favorable terms, if at all; our ability to maintain compliance with NASDAQ listing requirements; adverse side effects experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data analysis; the results of preclinical studies and clinical trials with respect to our products under development and whether such results will be indicative of results obtained in later clinical trials; our ability to obtain, maintain and enforce patent and other intellectual property protection for our products and product candidates; and the other factors described in Cornerstone Therapeutics' Annual Report on Form 10 K filed with the Securities and Exchange Commission (the SEC) on March 26, 2009 in the section entitled "Item 1A. Risk Factors", and other filings that we make with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this release.

ZYFLO CR(R) is a trademark of Cornerstone Therapeutics Inc.

    Investor Relations Contacts:
    FD
    Evan Smith/Brian Ritchie
    212-850-5600
    evan.smith@fd.com/brian.ritchie@fd.com

    Media Relations Contact:
    FD
    Robert Stanislaro
    212-850-5600
    robert.stanislaro@fd.com


'/>"/>
SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. OnCore(r) 9.0 Released: 'Top 5' Priorities and Collaborative Initiatives Cornerstones of Product Development
2. Cornerstone Therapeutics Announces New Board of Directors
3. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
4. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
5. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
6. Prime Therapeutics Announces Departure of President and Chief Executive Officer Timothy Dickman
7. InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer
8. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
9. TorreyPines Therapeutics, Inc. Hires Advisor to Evaluate Strategic Alternatives
10. Sirion Therapeutics Announces Positive Results From Interim Analysis of Phase II Trial and Receives FDA Fast Track Designation for Fenretinide
11. Intrinsic Therapeutics Announces CE Mark for Barricaid Anular Prosthesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... “Beyond and Back”: a true-life testimony of tragedy ... of published author Bonetta Rose, a wife, mother and grandmother committed to sharing her ... Faith Publishing, Bonetta Rose‘s new book presents actual events in the life of her ...
(Date:3/23/2017)... ... 2017 , ... “The Trainer”: an electrifying and suspenseful gunslinger novel with ... with an active imagination and an enthusiasm for action and adventure stories. ... Bill Hart, who sat looking at the thirty-three notches that lined the edges of ...
(Date:3/22/2017)... ... March 23, 2017 , ... ... solutions for drugs, biologics and consumer health products, today announced that it had ... currently taking place at the Suntec Singapore International Exhibition & Convention Centre, Singapore. ...
(Date:3/22/2017)... Georgia (PRWEB) , ... March 22, 2017 , ... ... time consuming and frustrating and this tool bypasses that. Healthcare facilities across ... identified an opportunity to offer their clients and hospitals, across the country, an ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Rett ... a devastating neurological disorder that afflicts 350,000 individuals worldwide. Rett Syndrome is ... and almost exclusively strikes females. Following a normal infancy, Rett Syndrome takes ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , 22 de marzo de 2017   ... líder de soluciones de productos y servicios para ... que ha adquirido EPL Archives, Inc., una organización ... clientes en todo el ciclo de vida de ... una muestra de archivo, almacenamiento de documentos y ...
(Date:3/22/2017)... , March 22, 2017 Under ... Chinese pharmaceutical packaging market size increased year by ... From 2017 to 2021, the market size will ... is expected to outnumber RMB140 billion in 2021, ... the rapid development of biological agents and supporting ...
(Date:3/22/2017)... RADNOR, Pennsylvania , 22. März 2017 ... führende unabhängige und weltweit tätige Anbieter von ... gibt heute den Erwerb von EPL Archives ... biologischer Stoffe, der Kunden im kompletten Zyklus ... bei Verwahrung von Proben, Speicherung von Dokumenten ...
Breaking Medicine Technology: